WP
IOVA icon

Woodline Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Woodline Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.67M Buy
1,363,226
+71,242
+6% +$271K 0.02% 667
2026
Q1 		$4.53M Buy
1,291,984
+724,304
+128% +$2.32M 0.02% 676
2025
Q4 		$1.55M Hold
567,680
– – 0.01% 804
2025
Q3 		$1.23M Hold
567,680
– – 0.01% 785
2025
Q2 		$976K Buy
567,680
+765
+0.1% +$1.9K 0.01% 806
2025
Q1 		$1.89M Buy
566,915
+3,338
+0.6% +$17.2K 0.01% 673
2024
Q4 		$4.17M Buy
563,577
+1,142
+0.2% +$10.6K 0.03% 523
2024
Q3 		$5.28M Buy
+562,435
New +$5.33M 0.04% 383
2024
Q2 		– Sell
-1,482,859
Closed -$22M – 614
2024
Q1 		$22M Sell
1,482,859
-121,847
-8% -$1.42M 0.2% 155
2023
Q4 		$13M Buy
1,604,706
+958,411
+148% +$5.01M 0.14% 201
2023
Q3 		$2.94M Buy
+646,295
New +$4.22M 0.03% 366
2022
Q4 		– Sell
-261,134
Closed -$2.5M – 802
2022
Q3 		$2.5M Sell
261,134
-238,636
-48% -$2.75M 0.04% 431
2022
Q2 		$5.52M Buy
499,770
+312,906
+167% +$4.1M 0.09% 247
2022
Q1 		$3.11M Sell
186,864
-431,839
-70% -$6.68M 0.05% 307
2021
Q4 		$11.8M Buy
618,703
+433,151
+233% +$9.54M 0.17% 164
2021
Q3 		$4.58M Buy
+185,552
New +$4.37M 0.07% 266
2021
Q2 		– Sell
-277,523
Closed -$8.79M – 611
2021
Q1 		$8.79M Buy
277,523
+255,949
+1,186% +$10.6M 0.19% 134
2020
Q4 		$1M Sell
21,574
-177,110
-89% -$7.03M 0.03% 209
2020
Q3 		$6.54M Buy
+198,684
New +$6.09M 0.21% 110
2020
Q2 		– Sell
-280,498
Closed -$8.4M – 167
2020
Q1 		$8.4M Buy
280,498
+137,857
+97% +$3.65M 0.6% 58
2019
Q4 		$3.95M Buy
+142,641
New +$3.24M 0.16% 97

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Woodline Partners's IOVA Position: Q2 2026 in Review

Woodline Partners increased its Iovance Biotherapeutics (IOVA) stake by 5.5% in Q2 2026, buying an estimated $271K and bringing the position to 1,363,226 shares worth $5.67M. The position accounts for 0.02% of the portfolio, ranked #667.

Woodline Partners first reported a position in IOVA in Q4 2019 and has held it in 21 quarters since. The position peaked at $22M in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Woodline Partners held 1,363,226 shares of Iovance Biotherapeutics worth $5.67M as of Q2 2026.
  • Woodline Partners bought 71,242 Iovance Biotherapeutics shares in Q2 2026, an estimated $271K.
  • Iovance Biotherapeutics made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #667 holding.
  • Woodline Partners first reported a position in Iovance Biotherapeutics in Q4 2019 and has held it in 21 quarters since.
  • Woodline Partners's Iovance Biotherapeutics position peaked at $22M in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.